Safety and Efficacy of Newer Oral Anticoagulants in Coronary Artery Disease Patients: A Prospective Observational Study
Abstract
Background: Coronary artery disease (CAD) is a major contributor to morbidity and mortality globally. Anticoagulation plays a pivotal role in managing thromboembolic complications. While traditional anticoagulants like warfarin and heparin are widely used, they are associated with limitations including bleeding risks and intensive monitoring. Newer oral anticoagulants (NOACs) such as apixaban and dabigatran offer a promising alternative.
Objective: To prospectively evaluate and compare the safety and adverse effect profile of newer oral anticoagulants (apixaban, dabigatran) with traditional agents (warfarin, heparin) in CAD patients under real-world clinical conditions.
Methods: A 12-month, open-label, parallel-group, observational study was conducted at Vijaya Hospital, Nellore. A total of 200 patients aged 30–60 with diagnosed CAD were included—100 on NOACs and 100 on older agents. Adverse drug reactions (ADRs) were evaluated using a structured questionnaire (CADSEQ), patient diaries, and WHO-UMC causality assessment.
Results: NOACs exhibited significantly fewer adverse events (13%) compared to warfarin/heparin (42%). Major bleeding, liver dysfunction, and hypersensitivity reactions were markedly lower in the NOAC group (p< 0.05). Patient adherence and satisfaction were improved with NOACs due to ease of administration and reduced monitoring needs.
Conclusion: NOACs demonstrate superior safety, tolerability, and compliance in CAD management. Their role should be expanded, especially in high-risk or poorly monitored populations. Further studies in special populations such as neonates or pediatric CAD cases may help shape safe usage protocols.
Downloads
References
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981–992.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139–1151.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–891.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis. The Lancet. 2014;383(9921):955–962.
Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine. 2017;377(14):1319–1330.
Beyer-Westendorf J, Gelbricht V, Förster K, et al. Safety of dabigatran in daily care: results from the Dresden NOAC registry. Thrombosis and Haemostasis. 2015;113(5):1113–1122.
De Caterina R, Ammentorp B, Darius H, et al. Management of bleeding complications in patients on oral anticoagulants: clinical practice considerations. American Journal of Medicine. 2020;133(7):748–761.
Hijazi Z, Oldgren J, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation. 2014;130(13):1133–1144.
Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal. 2012;33(21):2719–2747.
Li W-J, Palaiodimos L, et al. Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with atrial fibrillation: a meta-analysis. World Journal of Cardiology. 2021;13(4):82–94.
Kjerpeseth LJ, Selmer R, Ariansen I, et al. Comparative effectiveness of warfarin and direct oral anticoagulants in nonvalvular atrial fibrillation: a nationwide pharmacoepidemiological study. PLOS ONE. 2019;14(8):e0221500.
Chan Y-H, Kuo C-T, Yeh Y-H, et al. Safety and effectiveness of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2018;49(4):907–915.
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2013;369(22):2093–2104.
Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. Journal of the American College of Cardiology. 2014;63(4):321–328.
De Caterina R, Ammentorp B, Darius H, et al. Management strategies for bleeding complications on anticoagulants: clinical recommendations. European Heart Journal Supplements. 2020;22(Supplement I):I27–I34.
Caldeira D, Ferreira JJ, Pinto FJ, et al. Systematic review with meta-analysis: the risk of major bleeding with novel oral anticoagulants. American Journal of Medicine. 2015;128(2):113–120.
Lip GYH, Skjøth F, Nielsen PB, et al. Effectiveness and safety of standard-dose non-vitamin K antagonist oral anticoagulants and warfarin among patients with atrial fibrillation. Journal of the American Heart Association. 2018;7(6):e007951.
Barnes GD, Lucas E, Alexander GC, et al. National trends in ambulatory oral anticoagulant use. American Journal of Medicine. 2015;128(12):1300–1305.e2.
Chatterjee S, Sardar P, Biondi-Zoccai G, et al. New oral anticoagulants and the risk of gastrointestinal bleeding: a meta-analysis. Heart. 2013;99(11):834–839.
Hori M, Matsumoto M, Tanahashi N, et al. Safety and efficacy of rivaroxaban in Japanese patients with nonvalvular atrial fibrillation: the J-ROCKET AF study. Circulation Journal. 2012;76(9):2104–2111
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Murali Krishna Kandukuri , K. Karthickeyan
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
